Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05823285

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2023-04-21

150

Participants Needed

1

Research Sites

220 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.

CONDITIONS

Official Title

A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older and weight 40 kg or heavier
  • Histologically or cytologically confirmed advanced solid tumor
  • For Phase 1b, tumor must be GPC3 positive
  • Standard treatment has failed, is not tolerated, or no standard treatment exists
  • Adequate liver, blood, and kidney function
Not Eligible

You will not qualify if you...

  • Anti-tumor treatment within 4 weeks before first QLS31903 dose except specific conditions
  • Participation in another clinical trial within 4 weeks before first QLS31903 dose
  • Receipt of live or live attenuated vaccine within 30 days before first QLS31903 dose
  • Prior treatment targeting GPC3
  • Positive for HBsAg/HBcAb with HBV-DNA >10,000 copies/mL or positive for HCV-Ab with HCV-RNA >1,000 copies/mL
  • Central nervous system metastasis except stable asymptomatic or treated symptomatic brain metastases for more than 4 weeks
  • Carcinomatous meningitis or leptomeningeal disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan Zhongshan Hospital

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

Loading map...

Research Team

Y

Yan Chen, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here